| Subject: | FDA Approves Genetic Test for Identifying Patient Metabolism of Certain Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 1 Feb 2005 - 10:00 am |
| The FDA has cleared a new laboratory test system that identifies how well patients metabolize certain medications. The AmpliChip Cytochrome P450 Genotyping Test, manufactured by Roche Molecular Systems, Inc., a DNA microarray test that analyzes one of the genes from a family of genes called cytochrome P450 genes. These genes are which are involved in the break down certain drugs and other compounds in the liver. Variations in this gene can cause variations in a patient's ability to metabolize... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
